Patents Assigned to Institut National de la Sante et de la Recherche Medicale
  • Publication number: 20240057969
    Abstract: An ultrasound probe holding device configured to attach to the head of an infant for transfontanellar imaging is disclosed, including a head pad configured to be in contact with the head of the infant and including a central opening, wherein the head pad is configured to receive an ultrasound probe; a pad squeezer, including a central opening and configured to cooperate with the head pad to allow an axial guidance of the head pad along a guidance axis substantially perpendicular to a surface tangent to the head of the infant; a device holder configured to be attached to the head of the infant and exert a downward force on the pad squeezer, along said guidance axis; and a repellent configured to exert a repellent force between the pad squeezer and the head pad when the device holder exerts the downward force on the pad squeezer.
    Type: Application
    Filed: December 13, 2021
    Publication date: February 22, 2024
    Applicants: ICONEUS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Centre National de la Recherche Scientifique, ECOLE SUPÉRIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
    Inventors: Charlie Demene, Bruno-Felix Osmanski, Mickael Tanter, Jérôme Baranger, Olivier Baud
  • Patent number: 11905330
    Abstract: Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets.
    Type: Grant
    Filed: September 26, 2022
    Date of Patent: February 20, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS CITÉ, SORBONNE UNIVERSITÉ
    Inventors: Guido Kroemer, José Manuel Bravo San Pedro
  • Patent number: 11903982
    Abstract: Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectorations, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils.
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: February 20, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ETABLISSEMENT FRANCAIS DU SANG (EFS), UNIVERSITE DE BRETAGNE OCCIDENTALE, CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BREST
    Inventors: Rozenn Le Berre, Marie-Sarah Fangous, Gwenaelle Le Blay, Geneviève Hery-Arnaud, Rosyne Lagrafeuille
  • Patent number: 11905253
    Abstract: The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLC?1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: February 20, 2024
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE RENNES 1, CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, INSTITUT BERGONIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE BORDEAUX
    Inventors: Pierre Vacher, Patrick Legembre, Mickael Jean, Patrick Blanco, Pierre Van De Weghe
  • Patent number: 11896649
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an APJ receptor agonist.
    Type: Grant
    Filed: September 27, 2022
    Date of Patent: February 13, 2024
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Philippe Valet, Cedric Dray, Vincent Minville, Bernard Frances, Francois Labaste, Claire Vinel
  • Publication number: 20240034791
    Abstract: The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.
    Type: Application
    Filed: March 31, 2022
    Publication date: February 1, 2024
    Applicants: EMERGENCE THERAPEUTICS AG, UNIVERSITE D’AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS –
    Inventors: Jack ELANDS, Florence LHOSPPICE, Xavier PRÉVILLE, Daniel OLIVE, Marc LOPEZ
  • Patent number: 11883398
    Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: January 30, 2024
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Rosa Barreira Da Silva, Matthew Albert
  • Publication number: 20240010739
    Abstract: SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. The inventors produced an antibody that is directed against a surface antigen (i.e. CD40) of an antigen presenting cell (i.e. dendritic cell) wherein the heavy chain was conjugated to the receptor-binding domain of the Sars-Cov-2 spike protein for its use as vaccine. In particular, the inventors show that said vaccine induces circulating Ab-secreting hu-B cells, elicits S-specific IgG+ hu-B cells, elicits the expansion of central memory CD4+ hu-T cells and the emergence of effector memory CD4+ T cells, elicits the expansion of central memory CD8+ hu-T cells at and the emergence of effector memory CD8+ T cells at and finally induces Stem-cell like memory hu-CD8+ T cells.
    Type: Application
    Filed: November 10, 2021
    Publication date: January 11, 2024
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De Marne
    Inventors: Yves LEVY, Gérard ZURAWSKI, Mireille CENTLIVRE, Sandra ZURAWSKI, Véronique GODOT
  • Patent number: 11866484
    Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: January 9, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT CURIE, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
  • Publication number: 20240002521
    Abstract: Novel anti-human CD25 antibodies and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or an antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: January 4, 2024
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, ALDERAAN BIOTECHNOLOGY, UNIVERSITE D'AIX MARSEILLE, UNIVERSITÉ PARIS CITÉ, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
    Inventors: Daniel OLIVE, Armand BENSUSSAN, Jérôme GIUSTINIANI, Anne MARIE-CARDINE, Amaud FOUSSAT, Jemila HOUACINE
  • Publication number: 20240002522
    Abstract: Novel anti-human CD25 antibodies or antigen-binding fragments thereof and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or antigen-binding fragment thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: January 4, 2024
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, INSTITUT JEAN PAOLI & IRENE CALMETTES, ALDERANN BIOTECHNOLOGY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AIX MARSEILLE, UNIVERSITE PARIS CITE, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
    Inventors: Daniel OLIVE, Armand BENSUSSAN, Jerome GIUSTINIANI, Anne MARIE-CARDINE, Amaud FOUSSAT, Jemila HOUACINE
  • Patent number: 11857532
    Abstract: Friedreich ataxia (FRDA) is caused by a GAA repeat expansion in FXN gene that encodes a mitochondrial protein, frataxin, involved in iron sulfur complex (ISC) assembly. Frataxin deficiency results in abnormal ISC containing proteins, namely respiratory chain complex I-III and aconitases and accumulation of iron in brain and heart of patients. Here, the inventors show that FRDA fibroblasts are unable to limit iron uptake inducing a massive cytosolic iron accumulation and to a lesser extent in mitochondria. The inventors also observed increased transferrin receptor (TfR1) steady state levels and membrane TfR1 accumulation that they ascribed to impaired post-translational modification by palmitoylation as well as delayed transferrin recycling. Finally, the inventors showed that artesunate, dichloroacetate and Coenzyme-A improved TfR1 palmitoylation and thus represent candidate molecules for the treatment of patients with Friedreich ataxia.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: January 2, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), FONDATION IMAGINE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
    Inventors: Anne Agnès Rotig, Arnold Munnich, Floriane Petit
  • Publication number: 20230407264
    Abstract: The present invention relates to a population of cells comprising hepatic stem-like cells and therapeutic use thereof, for the treatment and the prevention of fulminant liver disorders. The hepatic stem-like cells according to the invention may be safely and reproducibly generated from pluripotent stem cells. In addition, although the hepatic stem-like cells according to the invention do not display the phenotype of physiologically mature hepatic cells, as they are lacking the albumin expression marker (ALB?), they may still be transplanted in a diseased liver with acute failure, rescue the diseased liver and promote liver regeneration. Moreover, various protocols of preparation of hepatic stem-like cells according to the invention may be implemented, all resulting in high quality and high yield of production. Finally, the hepatic stem-like cells according to the invention may be cryopreserved and may also be prepared as spheroid particles.
    Type: Application
    Filed: March 15, 2021
    Publication date: December 21, 2023
    Applicants: Goliver Therapeutics, Nantes Universite, Institut National de la Santé et de la Recherche Médicale
    Inventors: Tuan Huy Nguyen, Angélique Fourrier, Raphaël Rispal, Frédéric Delbos
  • Publication number: 20230393152
    Abstract: An identification of novel combinations of specific metabolites for neurodegenerative diseases for use as biomarkers in the early diagnosis of neurodegenerative diseases.
    Type: Application
    Filed: November 18, 2021
    Publication date: December 7, 2023
    Applicants: UNIVERSITE GRENOBLE ALPES, INSERM - Institut National de la Santé et de la Recherche Médicale
    Inventors: Sabrina BOULET, Florence FAUVELLE, David MALLET
  • Patent number: 11827637
    Abstract: The present invention concerns a compound of formula (I): or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity, in particular ERK2 activity.
    Type: Grant
    Filed: January 13, 2023
    Date of Patent: November 28, 2023
    Assignees: AGV Discovery, Institut National de la Sante et de la Recherche Medicale (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Université De Montpellier
    Inventors: Cédric Bories, Loïc Mathieu, Jean-François Guichou, Muriel Gelin, Aurélien Biechy
  • Publication number: 20230372350
    Abstract: A TRPA1 calcium channel inhibitor for use as a neuroprotectant in the treatment and/or prevention of the early stages of Alzheimer's disease and as an anti-inflammatory in the treatment and/or prevention of neuroinflammatory processes in Alzheimer's disease. In particular, the inhibitor HC030331 of the TRPA1 calcium channel for its use as a neuroprotectant in the treatment and/or prevention of the early stages of Alzheimer's disease and as an anti-inflammatory in the treatment and/or the prevention of the neuroinflammatory processes of Alzheimer's disease. A pharmaceutical composition comprising at least the inhibitor of the invention and at least one pharmaceutically acceptable excipient.
    Type: Application
    Filed: September 17, 2021
    Publication date: November 23, 2023
    Applicants: UNIVERSITE GRENOBLE ALPES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Mireille ALBRIEUX, Adrien PAUMIER, Anthony BOSSON, Alain BUISSON, Sylvie BOISSEAU
  • Patent number: 11821044
    Abstract: The present invention relates to methods for screening a subject for a cancer. In particular, the present invention relates to a method (A) for screening a subject for a cancer comprising the steps of i) extracting the cell free nucleic acids from a sample obtained from the subject, ii) determining the total concentration of mitochondrial cell free nucleic acids, ii) determining the total concentration of nuclear cell free nucleic acids iv) calculating the ratio of the level determined at step ii) to the concentration determined at step iii), v) comparing ratio determined at step iv) with a predetermined corresponding reference value and vi) concluding that the subject suffers from a cancer when the ratio determined at step iv) is lower than the predetermined corresponding reference value or concluding that the subject does not suffer from a cancer when the ratio determined at step iv) is higher than the predetermined corresponding reference value.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: November 21, 2023
    Assignees: INSTITUT NATIONAL DE LA SANTÈ ET DE LA RECHERCHE MÈDICALE, INSTITUT REGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIER
    Inventors: Alain Thierry, Safia El Messaoudi
  • Patent number: 11819492
    Abstract: The present invention relates to a compound of the following general formula (I): or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: November 21, 2023
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Sorbonne Universite, Universite de Poitiers, Centre Hospitalier Universitaire de Poitiers
    Inventors: Stéphane Bach, Marie-Thérèse Dimanche-Boitrel, Claire Delehouze, Thierry Hauet
  • Publication number: 20230364232
    Abstract: An immunogenic product including at least one immunoglobulin or fragment thereof conjugated with a carrier protein, wherein the at least one immunoglobulin is IgE and preferably wherein the IgE fragment includes the IgE C?3 domain, and wherein the carrier protein is preferably CRM197. Also the use of this immunogenic product for treating inflammatory disorders, and in particular allergic disorders.
    Type: Application
    Filed: September 17, 2021
    Publication date: November 16, 2023
    Applicants: NEOVACS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEUR
    Inventors: Laurent REBER, Pierre BRUHNS, Eva CONDE GARCIA, Marija BACKOVIC, Vincent SERRA, Géraldine GROUARD-VOGEL, Romain BERTRAND
  • Patent number: 11814683
    Abstract: Some embodiments are directed to a prognostic method for determining whether a subject is at risk of having the CLAD, comprising: measuring the expression level of POU2AF1 or BLK in a biological sample obtained from the subject; comparing the expression level of POU2AF1 or BLK with a predetermined reference value and concluding that the subject is at risk of having CLAD when the expression level of POU2AF1 or BLK is lower than the predetermined reference value.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: November 14, 2023
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique, Université de Nantes, Centre Hospitalier Universitaire de Nantes
    Inventors: Pierre-Joseph Royer, Antoine Magnan, Sophie Brouard, Richard Danger